PALVELLA THERAPEUTICS, INC.
PALVELLA THERAPEUTICS, INC. (PVLA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 pvla-ex99_1.htm EX-99.1 EX-99.1 Palvella Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update First module of the rolling NDA for QTORIN™ rapamycin for microcystic lymphatic malformations submitted to FDA, with completion of the NDA s
Biotech stocks rose as several companies issued updates. Wellgistics Health (WGRX) completed a rebrand to DataMEDS AI and will trade as MEDS; it reported Q1 2026 revenue of $0.929M and expects $1.775M in Q2. Dyadic (DYAI) saw a major shareholder sell. Palvella (PVLA) submitted the first NDA module for QTORIN. Sol-Gel (SLGL) expects SGT-610 Phase 3 data in Q4 2026.
Investing.com reports Monday’s stock movers, citing rallies in SanDisk (SNDK) up 5.39% and Intel (INTC) up 4.55%, plus gains in AMD and Western Digital (WDC). It also notes Iris Energy (IREN) raising an AI cloud revenue target to over $4bn, up 16.33%, and QumulusAI (QMLS) falling after ordering 1,632 NVIDIA Blackwell B300 GPUs.
Over the past 7 days, alphai's AI scored 1 news story mentioning PVLA (PALVELLA THERAPEUTICS, INC.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent PVLA coverage spans market movers, regulation and corporate actions.
In the last 30 days, PVLA insiders filed 4 SEC Form 4 transactions — no purchases and 4 sales ($642K). The most active reporter was Goin Kathleen, Chief Operating Officer, with 4 filings. 100% of activity was filed under pre-arranged Rule 10b5-1 plans.
Near-term catalyst is FDA rolling-review progress plus a defined NDA completion window, with follow-on upside tied to potential approval and planned standalone launch.
Rolling NDA progress is a tangible regulatory milestone that can re-rate risk for a clinical-stage biotech.
The article provides a downside move for PVLA without disclosing a new Pieris-specific driver.
This is an insider selling disclosure under a 10b5-1 plan; it may slightly affect sentiment but is not a fundamental change by itself.
NDA rolling review progress and FDA designations increase approval probability and can re-rate near-term biotech risk.
alphai scores every news story that mentions PVLA with an AI model for sentiment and relevance, and aggregates insider trades from PALVELLA THERAPEUTICS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
PALVELLA THERAPEUTICS, INC. (PVLA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 pvla-ex99_1.htm EX-99.1 EX-99.1 Palvella Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update First module of the rolling NDA for QTORIN™ rapamycin for microcystic lymphatic malformations submitted to FDA, with completion of the NDA s
4 min readBiotech stocks rose as several companies issued updates. Wellgistics Health (WGRX) completed a rebrand to DataMEDS AI and will trade as MEDS; it reported Q1 2026 revenue of $0.929M and expects $1.775M in Q2. Dyadic (DYAI) saw a major shareholder sell. Palvella (PVLA) submitted the first NDA module for QTORIN. Sol-Gel (SLGL) expects SGT-610 Phase 3 data in Q4 2026.
6 min readInvesting.com reports Monday’s stock movers, citing rallies in SanDisk (SNDK) up 5.39% and Intel (INTC) up 4.55%, plus gains in AMD and Western Digital (WDC). It also notes Iris Energy (IREN) raising an AI cloud revenue target to over $4bn, up 16.33%, and QumulusAI (QMLS) falling after ordering 1,632 NVIDIA Blackwell B300 GPUs.
4 min readGoin Kathleen (Chief Operating Officer) sold 4,302 shares of PALVELLA THERAPEUTICS, INC. (PVLA) at an average of $149.28 ($147.14–$150.25, $0.64M total) across 4 trades on 2026-07-15 under a Rule 10b5-1 trading plan.
2 min readPalvella Therapeutics (NASDAQ:PVLA) said it filed the initial module of its FDA NDA for QTORIN 3.9% rapamycin anhydrous gel to treat microcystic lymphatic malformations. The company plans to submit remaining NDA modules in late 2026 and prepare for a potential independent U.S. launch in early 2027. QTORIN has Orphan Drug, Fast Track, and Breakthrough Therapy designations.
4 min readPALVELLA THERAPEUTICS, INC. (PVLA) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001583648 0001583648 2026-06-29 2026-06-29 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor
2 min readPALVELLA THERAPEUTICS, INC. (PVLA) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001583648 0001583648 2026-06-10 2026-06-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Repor
3 min readPalvella Therapeutics said it completed an FDA pre-NDA meeting for QTORIN™ 3.9% rapamycin anhydrous gel in microcystic lymphatic malformations. The company expects to submit an NDA in the second half of 2026, using efficacy and safety data from its Phase 3 SELVA study plus supportive Phase 2 and real-world evidence. Palvella plans no additional efficacy study.
4 min readPalvella Therapeutics (Nasdaq: PVLA) said the U.S. Patent and Trademark Office issued U.S. Patent No. 12,636,273, exclusively licensed from Yale, covering topical mevalonate-pathway inhibition with QTORIN pitavastatin for porokeratosis, including DSAP, with protection into 2043. The company plans a Phase 2 DSAP trial in 2H 2026.
3 min readPalvella Therapeutics reported positive Phase 3 and Phase 2 clinical data for its topical QTORIN rapamycin gel, showing significant improvement in children with microcystic lymphatic malformations and cutaneous venous malformations. The company has secured multiple FDA designations, including Breakthrough Therapy, Orphan Drug, and Fast Track, for QTORIN rapamycin. Palvella plans to submit a New Drug Application in the second half of 2026 and initiate a new Phase 3 trial, aiming to establish QTORIN rapamycin as a first-in-disease therapy for rare vascular malformations.
3 min read
